- $22.14m
- $17.84m
- $14.24m
- 65
- 36
- 82
- 64
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.65 | ||
| Price to Tang. Book | 3.19 | ||
| Price to Free Cashflow | 29.45 | ||
| Price to Sales | 1.56 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.34% | ||
| Return on Equity | -22.58% | ||
| Operating Margin | -11.19% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 10.33 | 8.56 | 10.22 | 9.97 | 14.24 | 16.7 | 18.79 | 20.15% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Nephros, Inc. is a water technology company providing filtration solutions to the medical and commercial markets. The Company provides water filtration products and services, along with water-quality education. It operates through the Water Filtration segment. In the medical markets, it sells water filtration products. In the commercial markets, it manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Its products are marketed primarily to the food service, hospitality, convenience store, and health care markets. These commercial products are also marketed into medical markets, as supplemental filtration to its medical filters. The Company’s filters are primarily used in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, and in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate.
Directors
- Andrew Astor PRE (64)
- Daron Evans CEX (47)
- Wes Lobo OTH (44)
- Arthur Amron IND (64)
- Thomas Gwydir IND (56)
- Alisa Lask IND (50)
- Oliver Spandow IND (49)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 3rd, 1997
- Public Since
- September 21st, 2004
- No. of Shareholders
- 44
- No. of Employees
- 31
- Sector
- Professional & Commercial Services
- Industry
- Industrials
- Exchange
NASDAQ Capital Market- Shares in Issue
- 10,544,139
- Address
- 380 Lackawanna Pl, SOUTH ORANGE, 07079-1704
- Web
- https://www.nephros.com/
- Phone
- +1 2013435202
- Auditors
- BAKER TILLY US LLP
Upcoming Events for NEPH
Nephros Inc Annual Shareholders Meeting
Nephros Inc Annual Shareholders Meeting
Q2 2024 Nephros Inc Earnings Release
Similar to NEPH
Aeries Technology
NASDAQ Capital Market
ATIF Holdings
NASDAQ Capital Market
Augmedix
NASDAQ Capital Market
Baiya International
NASDAQ Capital Market
Bffi
NASDAQ Capital Market
FAQ
What is the Nephros share price?
As of Today at 19:15 UTC, shares in Nephros are trading at $2.10. This share price information is delayed by 15 minutes.
How has the Nephros share price performed this year?
Shares in Nephros last closed at $2.10 and the price had moved by +47.9% over the past 365 days. In terms of relative price strength the Nephros share price has outperformed the S&P500 Index by +23.07% over the past year.
What are the analyst and broker recommendations for Nephros?
The overall consensus recommendation for Nephros is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Nephros dividend yield?
Nephros does not currently pay a dividend.
Does Nephros pay a dividend?
Nephros does not currently pay a dividend.
When does Nephros next pay dividends?
Nephros does not currently pay a dividend.
How do I buy Nephros shares?
To buy shares in Nephros you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nephros?
As of the previous close price of $2.10, shares in Nephros had a market capitalisation of $22.14m.
Where are Nephros shares listed?
Here are the trading details for Nephros:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: NEPH
What kind of share is Nephros?
Based on an overall assessment of its quality, value and momentum Nephros is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nephros share price forecast for 2024?
The analyst consensus target price for shares in Nephros is $4.75. That is 126.19% above the last closing price of $2.10.
Analysts covering Nephros currently have a consensus Earnings Per Share (EPS) forecast of -$0.07 for the next financial year.
What is the trend in the Nephros share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nephros. Over the past six months, its share price has outperformed the S&P500 Index by +0.73%.
As of the last closing price of $2.10, shares in Nephros were trading -6.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nephros PE Ratio?
The Nephros PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nephros?
Nephros' management team is headed by:
- Andrew Astor - PRE
- Daron Evans - CEX
- Wes Lobo - OTH
- Arthur Amron - IND
- Thomas Gwydir - IND
- Alisa Lask - IND
- Oliver Spandow - IND